Search Results

You are looking at 1 - 3 of 3 items for

  • Author: Gordon Taylor Moffat x
  • Refine by Access: All x
Clear All Modify Search
Full access

Small Cell Lung Cancer in Light/Never Smokers – A Role for Molecular Testing?

Gordon Taylor Moffat, Tao Wang, and Andrew G. Robinson

This report describes the management of small cell lung cancer (SCLC) transformation in a patient with untreated ALK-mutated advanced disease and a minimal smoking history, and a separate case of a de novo SCLC in a lifelong nonsmoker found to have a potentially targetable ERBB2 alteration. In the first case, chemotherapy followed by a targeted inhibitor was chosen due to the presence of the ALK rearrangement, as well as a somewhat discordant response to induction chemotherapy, suggesting possible progression of the ALK inhibitor–sensitive component. Molecular testing for the identification of driver mutations should be considered in patients with SCLC who have light/never smoking histories in order to help understand the incidence and ultimate optimal management strategies.

Full access

CLO22-068: An Assessment of Extended Pembrolizumab Dosing and Outcomes in Advanced Non-Small Cell Lung Cancer Patients During the COVID-19 Pandemic

Gordon Taylor Moffat, Lilian Hanna, Wilma Hopman, Andrea S. Fung, and Pierre-Olivier Gaudreau

Full access

CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Lilian Hanna, Gordon Taylor Moffat, Wilma Hopman, Pierre-Olivier Gaudreau, and Andrea S. Fung